The impact of Girdin expression on recurrence-free survival in patients with luminal-type breast cancer
- 24 October 2013
- journal article
- research article
- Published by Springer Nature in Breast Cancer
- Vol. 22 (5), 445-451
- https://doi.org/10.1007/s12282-013-0501-3
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working GroupJNCI Journal of the National Cancer Institute, 2011
- Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011Annals of Oncology, 2011
- Clinical Implications for Girdin Protein Expression in Breast CancerCancer Investigation, 2011
- Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast CancerJNCI Journal of the National Cancer Institute, 2009
- Oestrogen-receptor-positive breast cancer: towards bridging histopathological and molecular classificationsJournal of Clinical Pathology, 2008
- An Actin-Binding Protein Girdin Regulates the Motility of Breast Cancer CellsCancer Research, 2008
- An overview of prognostic factors for long-term survivors of breast cancerBreast Cancer Research and Treatment, 2007
- Prognostic and Predictive Effects of Immunohistochemical Factors in High-Risk Primary Breast Cancer PatientsClinical Cancer Research, 2006
- Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now?Annals of Oncology, 2005
- Induction of NF-κB by the Akt/PKB kinaseCurrent Biology, 1999